The exp-log normal form of types

Lambda calculi with algebraic data types lie at the core of functional programming languages and proof assistants, but conceal at least two fundamental theoretical problems already in the presence of the simplest non-trivial data type, the sum type. First, we do not know of an explicit and implemented algorithm for deciding the beta-eta-equality of terms---and this in spite of the first decidability results proven two decades ago. Second, it is not clear how to decide when two types are essentially the same, i.e. isomorphic, in spite of the meta-theoretic results on decidability of the isomorphism. In this paper, we present the exp-log normal form of types---derived from the representation of exponential polynomials via the unary exponential and logarithmic functions---that any type built from arrows, products, and sums, can be isomorphically mapped to. The type normal form can be used as a simple heuristic for deciding type isomorphism, thanks to the fact that it is a systematic application of the high-school identities. We then show that the type normal form allows to reduce the standard beta-eta equational theory of the lambda calculus to a specialized version of itself, while preserving the completeness of equality on terms. We end by describing an alternative representation of normal terms of the lambda calculus with sums, together with a Coq-implemented converter into/from our new term calculus. The difference with the only other previously implemented heuristic for deciding interesting instances of eta-equality by Balat, Di Cosmo, and Fiore, is that we exploit the type information of terms substantially and this often allows us to obtain a canonical representation of terms without performing sophisticated term analyses

High pressure pre-treatments promote higher rate and degree of enzymatic hydrolysis of cellulose

The effect of high pressure (HP) pre-treatments on the subsequent enzymatic hydrolysis of cellulose from bleached kraft Eucalyptus globulus pulp by cellulase from Tricoderma viride was evaluated. Pressure pre-treatments of 300 and 400 MPa during 5–45 min, lead to both an increased rate and degree of hydrolysis, reaching values ranging from 1.5- to 1.9-fold, quantified by the formation of reducing sugars. Both the pressure and time under pressure influenced the enzymatic hydrosability of the cellulosic pulps, with the former being more important. The results indicate that the pressure pre-treatments promoted an increased accessibility of cellulose towards cellulase in the cell wall. The results obtained open promising possibilities, to contribute to overcome conventional limitations of enzymatic cellulose hydrolysis for the production of fermentable glucose, for the production of second generation bioethanol and chemicals by enhancement of both rate and yield of hydrolysis. The results are also of interest for the preparation of “pressure engineered” celullose with incremented tailored hydrolysis patterns

A study of cutaneous adverse drug reactions in the outpatient department of Dermatology at a tertiary care center in Gujarat, India

Background: The data for adverse cutaneous drug reactions (ACDRs) is limited in Gujarat. The ACDRs are one of the frequent ADRs and cause of significant morbidity and mortality in patients of all areas of healthcare today. They are responsible for significant number of hospital admissions. Thus, the present study emphasises on the need and importance of an effective pharmacovigilance programme.Methods: A prospective study was undertaken in a 183 cases tertiary care teaching hospital of India. Male to female ratio, most common class of drug, individual drug causing ACDR, common types of ACDRs Parameters were studied. Other Parameters like Causality, preventability and severe or non-severe reactions were analyzed.Results: Majority of the patients (48%) with CADR belonged to the age group 25-44 followed by 45-64 (28%). Most frequent adverse cutaneous drug reactions reported were Urticaria (40%), Maculopapular rash (25%) & Fixed drug eruptions (21%) in decreasing order of frequency. Majority of reactions (96%) were Bizarre/Unpredictable in nature. As a group, antimicrobials (46%) were most frequently associated with CADR followed by NSAIDs (31%) and antiepileptics (11%).  Most of the reactions (93%) were mild-moderate and probable (77%) in nature. Approximately 60% of ACDRs reported in this study were preventable.Conclusions: There was slight male preponderance except acneiform eruptions. Cotrimoxazole being the most common offending drug then after Ibuprofen, Phenytoin among the anti-inflammatory, analgesics, antiepileptics class. Causality assessment resulted in high score 77% of probable category

Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics

The taxanes are effective microtubule-stabilizing chemotherapy drugs that inhibit mitosis, induce apoptosis, and produce regression in a fraction of cancers that arise at many sites including the ovary. Novel therapeutic targets that augment taxane effects are needed to improve clinical chemotherapy response in CCNE1-amplified high grade serous ovarian cancer (HGSOC) cells. In this study, we conducted an siRNA-based kinome screen to identify modulators of mitotic progression in CCNE1-amplified HGSOC cells that may influence clinical paclitaxel response. PLK1 is overexpressed in many types of cancer, which correlates with poor prognosis. Here, we identified a novel synthetic lethal interaction of the clinical PLK1 inhibitor BI6727 and the microtubule-targeting drug paclitaxel in HGSOC cell lines with CCNE1-amplification and elucidated the underlying molecular mechanisms of this synergism. BI6727 synergistically induces apoptosis together with paclitaxel in different cell lines including a patient-derived primary ovarian cancer culture. Moreover, the inhibition of PLK1 reduced the paclitaxel-induced neurotoxicity in a neurite outgrowth assay. Mechanistically, the combinatorial treatment with BI6727/paclitaxel triggers mitotic arrest, which initiates mitochondrial apoptosis by inactivation of anti-apoptotic BCL-2 family proteins, followed by significant loss of the mitochondrial membrane potential and activation of caspase-dependent effector pathways. This conclusion is supported by data showing that BI6727/paclitaxel-co-treatment stabilizes FBW7, a component of SCF-type ubiquitin ligases that bind and regulate key modulators of cell division and growth including MCL-1 and Cyclin E. This identification of a novel synthetic lethality of PLK1 inhibitors and a microtubule-stabilizing drug has important implications for developing PLK1 inhibitor-based combination treatments in CCNE1-amplified HGSOC cells

Radial velocity observations at CASLEO

During three rounds, we have obtained 167 spectra of radial velocity standards using the 2.15 m telescope at CASLEO. The stars were selected from the IAU list (American Ephemeris, 1987). The spectrograms were secured on Kodak II a-0 plates developed 15 m in Kodak D-76 having a dispersion of 29 Å/mm in the blue region. We present here preliminary sets of wavelengths for lines and blends in two different spectral types.Asociación Argentina de Astronomí

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma. Methods: In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 hospitals and cancer centres across 11 countries. Eligible patients were aged 18 years or older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved complete or partial response to their last platinum-based regimen, had a cancer antigen 125 concentration of less than the upper limit of normal, had a performance status of 0–1, and had adequate organ function. Patients were ineligible if they had symptomatic or untreated central nervous system metastases, had received anticancer therapy 14 days or fewer before starting the study, or had received previous treatment with a poly(ADP-ribose) polymerase inhibitor. We randomly allocated patients 2:1 to receive oral rucaparib 600 mg twice daily or placebo in 28 day cycles using a computer-generated sequence (block size of six, stratified by homologous recombination repair gene mutation status, progression-free interval after the penultimate platinum-based regimen, and best response to the most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder were masked to assignments. The primary outcome was investigator-assessed progression-free survival evaluated with use of an ordered step-down procedure for three nested cohorts: patients with BRCA mutations (carcinoma associated with deleterious germline or somatic BRCA mutations), patients with homologous recombination deficiencies (BRCA mutant or BRCA wild-type and high loss of heterozygosity), and the intention-to-treat population, assessed at screening and every 12 weeks thereafter. This trial is registered with ClinicalTrials.gov, number NCT01968213; enrolment is complete. Findings: Between April 7, 2014, and July 19, 2016, we randomly allocated 564 patients: 375 (66%) to rucaparib and 189 (34%) to placebo. Median progression-free survival in patients with a BRCA-mutant carcinoma was 16·6 months (95% CI 13·4–22·9; 130 [35%] patients) in the rucaparib group versus 5·4 months (3·4–6·7; 66 [35%] patients) in the placebo group (hazard ratio 0·23 [95% CI 0·16–0·34]; p<0·0001). In patients with a homologous recombination deficient carcinoma (236 [63%] vs 118 [62%]), it was 13·6 months (10·9–16·2) versus 5·4 months (5·1–5·6; 0·32 [0·24–0·42]; p<0·0001). In the intention-to-treat population, it was 10·8 months (8·3–11·4) versus 5·4 months (5·3–5·5; 0·36 [0·30–0·45]; p<0·0001). Treatment-emergent adverse events of grade 3 or higher in the safety population (372 [99%] patients in the rucaparib group vs 189 [100%] in the placebo group) were reported in 209 (56%) patients in the rucaparib group versus 28 (15%) in the placebo group, the most common of which were anaemia or decreased haemoglobin concentration (70 [19%] vs one [1%]) and increased alanine or aspartate aminotransferase concentration (39 [10%] vs none). Interpretation: Across all primary analysis groups, rucaparib significantly improved progression-free survival in patients with platinum-sensitive ovarian cancer who had achieved a response to platinum-based chemotherapy. ARIEL3 provides further evidence that use of a poly(ADP-ribose) polymerase inhibitor in the maintenance treatment setting versus placebo could be considered a new standard of care for women with platinum-sensitive ovarian cancer following a complete or partial response to second-line or later platinum-based chemotherapy. Funding: Clovis Oncology

Isomorphisms of types in the presence of higher-order references (extended version)

We investigate the problem of type isomorphisms in the presence of higher-order references. We first introduce a finitary programming language with sum types and higher-order references, for which we build a fully abstract games model following the work of Abramsky, Honda and McCusker. Solving an open problem by Laurent, we show that two finitely branching arenas are isomorphic if and only if they are geometrically the same, up to renaming of moves (Laurent's forest isomorphism). We deduce from this an equational theory characterizing isomorphisms of types in our language. We show however that Laurent's conjecture does not hold on infinitely branching arenas, yielding new non-trivial type isomorphisms in a variant of our language with natural numbers

Influence of moisture contents on the fast pyrolysis of trommel fines in a bubbling fluidized bed reactor

In this study, the effect of moisture contents [2.69 wt% (bone-dry), 5 wt% and 10 wt%] on product yields and process conversion efficiency during fast pyrolysis of a pre-treated trommel fines feedstock was investigated at 500 °C. Experiments were carried out using a 300 g h −1 bubbling fluidised bed rig. Yields of organic liquids ranged from 15.2 to 19.6 wt% of feedstock, which decreased with increasing moisture content. Hence, the bone-dry feedstock gave the maximum yield and consequently the highest process conversion efficiency of 43%. Increased moisture content also led to increase formation of unidentified gas products, indicating increased conversion of organic liquids. Due to the high ash content of the feedstocks, about 52 wt% solid residues, containing around 82% ash was recovered in the char pot in each case. Hence, to maximize oil yields during fast pyrolysis, trommel fines would require extensive drying to remove the original 46 wt% moisture as well as reducing the ash content considerably. XRF analysis of the ash in the feedstock and solid residues showed that the main elements present included Ca, Si, Fe, Pb, K, Cl and Al. Apart from the presence of Pb (which may be from the glass contents of the feedstock), the solid residues could be used for land reclamation or co-incinerated at cement kilns for cement manufacture

Valorization of eucalyptus wood by glycerol-organosolv pretreatment within the biorefinery concept: an integrated and intensified approach

The efficient utilization of lignocellulosic biomass and the reduction of production cost are mandatory to attain a cost-effective lignocellulose-to-ethanol process. The selection of suitable pretreatment that allows an effective fractionation of biomass and the use of pretreated material at high-solid loadings on saccharification and fermentation (SSF) processes are considered promising strategies for that purpose. Eucalyptus globulus wood was fractionated by organosolv process at 200 C for 69 min using 56% of glycerol-water. A 99% of cellulose remained in pretreated biomass and 65% of lignin was solubilized. Precipitated lignin was characterized for chemical composition and thermal behavior, showing similar features to commercial lignin. In order to produce lignocellulosic ethanol at high-gravity, a full factory design was carried to assess the liquid to solid ratio (3e9 g/g) and enzyme to solid ratio (8e16 FPU/g) on SSF of delignified Eucalyptus. High ethanol concentration (94 g/L) corresponding to 77% of conversion at 16FPU/g and LSR ¼ 3 g/g using an industrial and thermotolerant Saccharomyces cerevisiae strain was successfully produced from pretreated biomass. Process integration of a suitable pretreatment, which allows for whole biomass valorization, with intensified saccharification-fermentation stages was shown to be feasible strategy for the co-production of high ethanol titers, oligosaccharides and lignin paving the way for cost-effective Eucalyptus biorefinery.Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UID/BIO/04469/2013 unit and COMPETE 2020 (POCI-01-0145-FEDER-006684). The authors also thank the FCT for finacial support under the scope of the Project RECI/BBB-EBI/0179/2012 (FCOMP-01-0124-FEDER-027462). AR was supported by Postdoctoral Fellowship PlanI2C/2014 funded by Xunta of Galicia (Spain